QCZ484 and inclisiran together for high blood pressure with high cholesterol
Tests QCZ484 with inclisiran in adults with high blood pressure and cholesterol.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
Key facts
- Where
- Boca Raton, Brandon, Canton, Chicago, Cooper City, Coral Gables, Doral, Foley, Ft. Washington, Houston, Jacksonville, Lanham, Lincoln, Little River, Los Angeles, Manassas, Miami, Miami Lakes, Monroe, Niles, Northridge, Pembroke Pines, Richmond, Saint Augustine, Saraland, West Monroe, and Wichita, United StatesSee the 27 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07610278, who can take part
Where in United States
- Flourish Medical Clinical TrialsBoca Raton, United StatesTaking people
- Clinical Research of Brandon, LLCBrandon, United StatesTaking people
- East Coast ResearchCanton, United StatesTaking people
- Great Lakes Clinical TrialsChicago, United StatesTaking people
- ALL Medical Research, LLCCooper City, United StatesTaking people
- AMR MiamiCoral Gables, United StatesTaking people
- Universal Axon Clinical ResearchDoral, United StatesTaking people
- G and L Research LLCFoley, United StatesTaking people
- Anderson Medical ResearchFt. Washington, United StatesTaking people
- Synergy Group Medical,LLCHouston, United StatesTaking people
- East Coast Institute for ResearchJacksonville, United StatesTaking people
- Capitol Cardiology AssociatesLanham, United StatesTaking people
- Clinical Trials ResearchLincoln, United StatesTaking people
- Walker Family CareLittle River, United StatesTaking people
- Downtown L.A. Research Center, Inc.Los Angeles, United StatesTaking people
- Manassas Clinical Research CenterManassas, United StatesTaking people
- Entrust Clinical ResearchMiami, United StatesTaking people
- Inpatient Research Clinical LLCMiami Lakes, United StatesTaking people
- Monroe Biomedical ResearchMonroe, United StatesTaking people
- AMR ChicagoNiles, United StatesTaking people
- Valley Clinical TrialsNorthridge, United StatesTaking people
- American Research Centers of FLPembroke Pines, United StatesTaking people
- Dominion Medical AssociatesRichmond, United StatesTaking people
- East Coast Inst for Research LLCSaint Augustine, United StatesTaking people
- The Center for Clinical TrialsSaraland, United StatesTaking people
- Monroe Research, LLCWest Monroe, United StatesTaking people
- Alliance for Multispecialty ResearchWichita, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07610278
- Record updated
- 30 July 2026
- Original description
This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia.Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Factorial Design Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of HDY015 Administered as a Free Combination of QCZ484 and Inclisiran Compared to QCZ484, Inclisiran, and Placebo in Participants With Hypertension and Concomitant Hypercholesterolemia
This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia.
Inclusion: Males or females aged 18 to 75 years; Diagnosis of primary hypertension; Treatment with either no, or up to 2 antihypertensive medications at a stable dose for at least 4 weeks preceding screening; Systolic blood pressure ≥140 and <165 mmHg based on the mean of 3 sitting measurements based on office blood pressure monitoring; Diagnosis of hypercholesterolemia including heterozygous familial hypercholesterolemia unable to reach LDL-C goals with a stable dose of statin treatment for at least 4 weeks prior to screening as per Investigator judgement, guidelines and local practice (if tolerated and not contraindicated) with or without bempedoic acid and with or without ezetimibe prescribed according to local guidance, at a stable dose for at least 4 weeks preceding Screening Visit 1; The following parameters must be confirmed at Screening Visit 2:; Fasting serum LDL-C ≥70 mg/dL and <190 mg/dL using Friedewald equation; Fasting triglyceride <400 mg/dL.
Exclusion: Treatment with certain medications and/or unable to comply with prohibited medications requirements; Other protocol inclusion/exclusion criteria may apply; Symptomatic orthostatic hypotension.